RHY.AU · Rhythm Biosciences Limited

-

Please sign in to comment on RHY.AU

1 Comment

Admin

4 years, 1 month ago

Rhythm Biosciences Limited is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Rhythm Biosciences Limited's total revenue sank by 60.3% to $10K since the same quarter in the previous year.

Its net income has dropped by 5.0% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 51.0% to $-770K since the same quarter in the previous year.

Based on the above factors, Rhythm Biosciences Limited gets an overall score of 1/5.

ISIN	AU000000RHY2
Exchange	AU
CurrencyCode	AUD
Sector	Healthcare
Industry	Diagnostics & Research

Beta	2.04
Market Cap	18M
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

Rhythm Biosciences Limited

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

RHY.AU · Rhythm Biosciences Limited

-

Rhythm Biosciences Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Rhythm Biosciences Limited using a moving average strategy